Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXSTW4zOC53IN88US=> Mm\xO|IhcA>? M1jIemROW09? NUnReWVLUUN3ME2wMlA1KM7:TR?= NVjQbWZCOjZzM{[2PFQ>
LS174T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGwMlUh|ryP M4rESVczKGh? NHnj[HRFVVOR M2\ZTWlEPTB;MD6wOUDPxE1? M{GwelI3OTN4Nki0
T84 NHzXTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzUUFFPOC53IN88US=> MVq3NkBp NWTqXHJPTE2VTx?= NHrQbnZKSzVyPUCuNFkh|ryP NV\4T5lzOjZzM{[2PFQ>
LS180 NF3hcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlUh|ryP MUO3NkBp NUflRYZ3TE2VTx?= M3yyfWlEPTB;MTFOwG0> MoPHNlYyOzZ4OES=
SW948 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlUh|ryP M{LNSlczKGh? NF[1W4lFVVOR NUT4dJlqUUN3ME2xJO69VQ>? M{PFWFI3OTN4Nki0
HCT15 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOwMlUh|ryP NF;BUmU4OiCq NWfxfJBSTE2VTx?= MlXYTWM2ODxyLkSg{txO NHTzZYszPjF|Nk[4OC=>
DLD-1 NXjycVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVewMlUh|ryP NXTPPZl1PzJiaB?= MX;EUXNQ NIi1e|dKSzVyPECuPEDPxE1? NG\nc4gzPjF|Nk[4OC=>
MIP-101 NXq4eWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzBNE42KM7:TR?= NUP4eJlPPzJiaB?= NYS5VpdoTE2VTx?= NV22b5M4UUN3ME2xJO69VQ>? Mk\jNlYyOzZ4OES=
SNU1544 M1jiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Tt[FAvPSEQvF2= NFnuOWE4OiCq NHjNW2FFVVOR NIPKVGpKSzVyPUGg{txO MmC4NlYyOzZ4OES=
OCI-Ly10 M2XXdWN6fG:2b4jpZ{BCe3OjeR?= M4LOUFczKGh? MYjEUXNQ NHjOdoNKSzVyPUCuNFU5KM7:TR?= Mnf0NlU5Pzh|M{G=
SU-DHL2 MXXDfZRwfG:6aXOgRZN{[Xl? M1T4[lczKGh? Ml7mSG1UVw>? MUDJR|UxRTBwMEGg{txO NXj0NYFpOjV6N{izN|E>
OCI-LY7 M{jyZWN6fG:2b4jpZ{BCe3OjeR?= MVq3NkBp MnvaSG1UVw>? NVn0Z295UUN3ME2wMlA5OSEQvF2= MUOyOVg4QDN|MR?=
SU-DHL6 NYTUXYh3S3m2b4TvfIlkKEG|c3H5 NX2wOGk3PzJiaB?= MXfEUXNQ NHOwUGFKSzVyPUCuOFgzKM7:TR?= MXiyOVg4QDN|MR?=
Jeko-1 M2ruNWN6fG:2b4jpZ{BCe3OjeR?= MUO3NkBp MkLNSG1UVw>? MmO4TWM2OD1yLkCyPUDPxE1? NWTtN|BVOjV6N{izN|E>
JVM-2 MYDDfZRwfG:6aXOgRZN{[Xl? MW[3NkBp NIrn[3dFVVOR NXKyW3NKUUN3ME2wMlAyKM7:TR?= M1nTXFI2QDd6M{Ox
Rec-1 NIT4bFdEgXSxdH;4bYMhSXO|YYm= MYS3NkBp NYXWb2JITE2VTx?= M{XlcGlEPTB;MD6wPFch|ryP MUOyOVg4QDN|MR?=
Z-138 MmrhR5l1d3SxeHnjJGF{e2G7 MkDtO|IhcA>? M2DERmROW09? MUHJR|UxRTBwMEGzJO69VQ>? Mn7YNlU5Pzh|M{G=
H9 NXP5[ZZ1S3m2b4TvfIlkKEG|c3H5 MkLzO|IhcA>? NWLaNYtPTE2VTx?= MV;JR|UxRTBwNjFOwG0> M4rwRlI2QDd6M{Ox
HH Ml3wR5l1d3SxeHnjJGF{e2G7 NWSwcHh7PzJiaB?= NHXJUGVFVVOR MU\JR|UxRTBwNzFOwG0> NYXCPIQxOjV6N{izN|E>
DND41 MWTDfZRwfG:6aXOgRZN{[Xl? NVnVOnkxPzJiaB?= Mnv3SG1UVw>? NWTNZ3ljUUN3ME2wMlEh|ryP MY[yOVg4QDN|MR?=
CCL119 MULDfZRwfG:6aXOgRZN{[Xl? NFmyd5E4OiCq MXXEUXNQ NEXxb2VKSzVyPUCuNFYzKM7:TR?= NYDBOIFYOjV6N{izN|E>
J.Cam 1.6 M3vLOWN6fG:2b4jpZ{BCe3OjeR?= NIPKR484OiCq MnKzSG1UVw>? NGD2fnJKSzVyPUCuNVA2KM7:TR?= NVXtNm1JOjV6N{izN|E>
Sup-T1 MmjBR5l1d3SxeHnjJGF{e2G7 NES0NIw4OiCq MWLEUXNQ NU\EcmE4UUN3ME2yMlE1OiEQvF2= MVGyOVg4QDN|MR?=
Tib 152 NH34RWJEgXSxdH;4bYMhSXO|YYm= NUnMNoVvPzJiaB?= M2LR[WROW09? NESwPY9KSzVyPUCuPEDPxE1? NH;GZoQzPTh5OEOzNS=>
MCF7 NXm1T|Y1TnWwY4Tpc44hSXO|YYm= MoHLOUDPxE1? M3nuRVI1KGh? NWjp[2o2TE2VTx?= NFfi[YJKdmS3Y3XzJGczN01iYYLy[ZN1 MYKyOVg{PDRyMR?=
MDA-MB-231 MnPzSpVv[3Srb36gRZN{[Xl? M1\tdlUh|ryP M2\sTlI1KGh? NGH5bGVFVVOR NWrm[ldXUW6mdXPld{BIOy:PIHHydoV{fA>? NGLMNXYzPTh|NESwNS=>
MCF7 M2TOSWZ2dmO2aX;uJGF{e2G7 M3TrclUh|ryP M4n4d|I1KGh? M4r3OWROW09? NWnjeWtiTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> NVfxclJqOjV6M{S0NFE>
MCF7 Mn3wSpVv[3Srb36gRZN{[Xl? M1fYXVUh|ryP M4PYdlI1KGh? MYDEUXNQ M2r2fGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz MYOyOVg{PDRyMR?=
MCF7 MXzGeY5kfGmxbjDBd5NigQ>? NUjTNnlwPSEQvF2= M3TiN|I1KGh? M1HPUmROW09? NH[4RlhF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx MWCyOVg{PDRyMR?=
MCF7 MlXFSpVv[3Srb36gRZN{[Xl? Mmf6OUDPxE1? MUSyOEBp NWPLVopmTE2VTx?= M4TF[mlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy MX2yOVg{PDRyMR?=
MCF7 M3;PXGZ2dmO2aX;uJGF{e2G7 MYO1JO69VQ>? M{PJUFI1KGh? Mnf3SG1UVw>? M1m0NWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= M17qS|I2QDN2NECx
MDA-MB-231 M4Cxd2Z2dmO2aX;uJGF{e2G7 NFXyW5c2KM7:TR?= MoP5NlQhcA>? NYrv[2dxTE2VTx?= M2riNGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= MlXXNlU5OzR2MEG=
MDA-MB-231 NWrC[m1ZTnWwY4Tpc44hSXO|YYm= NGLGZpgyKM7:TR?= MkjmNlQhcA>? M3XvTGROW09? M1LjcGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz M{CxclI2QDN2NECx
MDA-MB-231 MmDhSpVv[3Srb36gRZN{[Xl? MnXtOUDPxE1? NGPDNlAzPCCq NXn1d5pJTE2VTx?= NHXPdHNF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx M2nrZlI2QDN2NECx
MDA-MB-231 MWTGeY5kfGmxbjDBd5NigQ>? M{XXVFUh|ryP MV[yOEBp MWXEUXNQ MmjkTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> NEflWGUzPTh|NESwNS=>
MDA-MB-231 MnjQSpVv[3Srb36gRZN{[Xl? Mlm2OUDPxE1? MXGyOEBp M2LjOGROW09? M3r0Xmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= NHm2VHQzPTh|NESwNS=>
MDA-MB-231 MknRSpVv[3Srb36gRZN{[Xl? NGrhSFA2KM7:TR?= NWTUS2ozOjRiaB?= NWjXTVBpTE2VTx?= MUjJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz NFzxSpYzPTh|NESwNS=>
MCF7 M33Oc2Fxd3C2b4Ppd{BCe3OjeR?= M3vsRVUh|ryP M1LLSlI1KGh? MlzhSG1UVw>? NV\mZ5ZiUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= MkXzNlU5OzR2MEG=
MDA-MB-231 Mlq2RZBweHSxc3nzJGF{e2G7 MVq1JO69VQ>? NW\Melg1OjRiaB?= NIf0ZlVFVVOR M4rSd2lv\HWlZYOgZZBweHSxdHnjJIRm[XSq NYHOcFRjOjV6M{S0NFE>
MCF7 MUHGeY5kfGmxbjDBd5NigQ>? M3HCcFEh|ryP NXWxO3dMPzJiaB?= NFezRmlFVVOR NFq0WY5KdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NF[ze40zPTh|NESwNS=>
MDA-MB-231 MV;GeY5kfGmxbjDBd5NigQ>? M1fU[lEh|ryP MXe3NkBp MmjuSG1UVw>? M2\5Vmlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= NX\0dYg6OjV6M{S0NFE>
U-2 OS NYD5[XN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK1NEDPxE1? M3zJZVI1KGh? NX3OV21HTE2VTx?= MXPJR|UxRTF4Lk[g{txO NUPocVJGOjV5OUK4NVE>
MG-63 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHPUWM2OCEQvF2= MYWyOEBp Mo\6SG1UVw>? NGPST2NKSzVyPUmuOUDPxE1? MViyOVc6OjhzMR?=
U-2 OS NY\hVmpiSXCxcITvd4l{KEG|c3H5 NYfac25wPSEQvF2= NGfBZnMzPCCq MX3EUXNQ M4TRemlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> M2TZbFI2Pzl{OEGx
MG-63 M4fUSmFxd3C2b4Ppd{BCe3OjeR?= NITnNpk2KM7:TR?= NUG1VGZ[OjRiaB?= NGfRclZFVVOR M3fDfGlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> NEPDWpYzPTd7MkixNS=>
U-2 OS NH;YNGVHfW6ldHnvckBCe3OjeR?= MX61JO69VQ>? MmjMNlQhcA>? MWfEUXNQ MXLQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> M4XFdFI2Pzl{OEGx
MG-63 NGrJVlFHfW6ldHnvckBCe3OjeR?= MnPMOUDPxE1? M13zXFI1KGh? M2jjRWROW09? MWXQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NVjIbGtbOjV5OUK4NVE>
PANC-1 NFzzT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnZXG42OCEQvF2= NHL1fZkzPCCq M3\0dGROW09? NYDIPWxTUUN3ME23MlEh|ryP NUnnOGJNOjV4M{KyNlU>
BxPC-3 NVjMTHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED6UFI2OCEQvF2= MVOyOEBp Mn3ZSG1UVw>? MlK2TWM2OD14Lkig{txO M2KySlI2PjN{MkK1
PANC-1 M2XLfGZ2dmO2aX;uJGF{e2G7 NYriSVJTPSEQvF2= MmnRNlQhcA>? M4LZSGROW09? NULiXlhrUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn Mn7WNlU3OzJ{MkW=
BxPC-3 M{LTVmZ2dmO2aX;uJGF{e2G7 NGHTcII2KM7:TR?= MmrINlQhcA>? MYXEUXNQ NUnZRY84UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MX:yOVY{OjJ{NR?=
PANC-1 MUfGeY5kfGmxbjDBd5NigQ>? NFu3UJg2KM7:TR?= NFmwRoQzPCCq MoXrSG1UVw>? MmXGTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MoLwNlU3OzJ{MkW=
BxPC-3 MVXGeY5kfGmxbjDBd5NigQ>? M4\h[FUh|ryP NF;CXVUzPCCq NEXqdYVFVVOR Mor0TY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MVGyOVY{OjJ{NR?=
SKOV3 MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS5NVAxKM7:TR?= MX:yOEBp NUTJNnRKTE2VTx?= NEDrc49KSzVyPUKwMlQ5KM7:TR?= M4fu[|I2PjJ2N{Ww
OVCAR4 M4foV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7Z[4R1OTByIN88US=> MmrRNlQhcA>? NEj0WZVFVVOR MWTJR|UxRTJ{LkGzJO69VQ>? MnrPNlU3OjR5NUC=
SKOV3 NH;4fHZHfW6ldHnvckBCe3OjeR?= M{[zXFUh|ryP M1e0PVczKGh? M1fSUWROW09? MUXJcoR2[2W|IFeyM20h[XK{ZYP0 M1TOOFI2PjJ2N{Ww
OVCAR4 NYi4e3RHTnWwY4Tpc44hSXO|YYm= NIjOXlU2KM7:TR?= NHTFZVQ4OiCq MnHISG1UVw>? MmOwTY5lfWOnczDHNk9OKGG{cnXzeC=> MXeyOVYzPDd3MB?=
SKOV3 MWrBdI9xfG:|aYOgRZN{[Xl? M{\iPFUh|ryP Ml[wNlQhcA>? MXrEUXNQ MmjJTY5lfWOnczDhdI9xfG:|aYO= M{L6cVI2PjJ2N{Ww
OVCAR4 NV;jbXZCSXCxcITvd4l{KEG|c3H5 M4fUNFUh|ryP MlzKNlQhcA>? MYTEUXNQ M2DuPGlv\HWlZYOgZZBweHSxc3nz MkX6NlU3OjR5NUC=
AGS NHnEfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfTNlUh|ryP MYKyOEBp NVHHWYJ1TE2VTx?= MX7JR|UxRTF7LkC5JO69VQ>? M2TBe|I2PjB7OUKz
NCI-N78 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm0elEzPSEQvF2= MYWyOEBp MXvEUXNQ NGCxbWVKSzVyPUK2MlM{KM7:TR?= NFLtZm0zPTZyOUmyNy=>
AGS MVnBdI9xfG:|aYOgRZN{[Xl? M{jkRVUh|ryP MoL0NlQhcA>? MX;EUXNQ NVzUTWhmUW6mdXPld{BieG:ydH;zbZM> Ml;iNlU3ODl7MkO=
NCI-N78 MUjBdI9xfG:|aYOgRZN{[Xl? NX:xN4M1PSEQvF2= MlLrNlQhcA>? MXjEUXNQ M17CNmlv\HWlZYOgZZBweHSxc3nz M2jtdFI2PjB7OUKz
AGS M1nTSGZ2dmO2aX;uJGF{e2G7 M2[zU|Uh|ryP M37t[lI1KGh? Mn35SG1UVw>? M4LhSWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NHvJOYIzPTZyOUmyNy=>
NCI-N78 NVnXZ2ZITnWwY4Tpc44hSXO|YYm= NX24Z5lkPSEQvF2= MVqyOEBp MWjEUXNQ M{n5Tmlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? MlWyNlU3ODl7MkO=
HSC-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v0NlEh|ryP M4fUVlQ5KGh? NInON4dKSzVyPUCuOVQh|ryP NEXsNXUzPTN4NkG0Ny=>
GB30 NInkcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[yT5F3OSEQvF2= NUDEdHpGPyCm NVHnfYVlTE2VTx?= MYjJR|UxRTBwMEGxJO69VQ>? MWeyOVExPjR{OB?=
GB9 NIL5VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxJO69VQ>? NEfZN484KGR? M{jabmROW09? NXfDNWR{UUN3ME2wMlAzPCEQvF2= MoLtNlUyODZ2Mki=
GB169 NFrrPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxJO69VQ>? NVW5VZR{PyCm NUXiNphSTE2VTx?= NV;iUY9YUUN3ME2wMlA{OiEQvF2= M3f1SlI2OTB4NEK4
T24 NXfoTpBKTnWwY4Tpc44hSXO|YYm= Mk\UNUDPxE1? NG\LNpE1QCCq M1nwcWROW09? M3y5W2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= M3\mVFI{PDB|NkOz
RT4 MUTGeY5kfGmxbjDBd5NigQ>? MlLrNUDPxE1? M3q3XVQ5KGh? MV7EUXNQ NIjpXYhKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MXiyN|QxOzZ|Mx?=
UM-UC-3 M{OzU2Z2dmO2aX;uJGF{e2G7 M{C0cVEh|ryP NVvPenZqPDhiaB?= NY\KfY9KTE2VTx?= NWSzfZZ7UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MlLSNlM1ODN4M{O=
T24 MlT4RZBweHSxc3nzJGF{e2G7 MV:zMlE3KM7:TR?= MWS5OkBp M2\XOGROW09? MVfJR|UxRTBwMEOwOkDPxE1? MYKyN|QxOzZ|Mx?=
RT4 NEXnZVdCeG:ydH;zbZMhSXO|YYm= NY\DV4R3Oy5zNjFOwG0> M{j5OVk3KGh? M4fLOWROW09? MnjkTWM2OD1yLkGxPVgh|ryP MoT1NlM1ODN4M{O=
UM-UC-3 MX\BdI9xfG:|aYOgRZN{[Xl? MlHGN{4yPiEQvF2= MofoPVYhcA>? NVPFOFVpTE2VTx?= NWLzSpVSUUN3ME2wMlA1PDlizszN MoWxNlM1ODN4M{O=
OVCAR-5 MmDhSpVv[3Srb36gRZN{[Xl? NFLmfnY2OCCwTR?= MULJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>? MYmyN|M{PDN{Nx?=
SKOV3ip2 MXjGeY5kfGmxbjDBd5NigQ>? M3;HeFUxKG6P M2fFemlvcGmkaYTzJINmdGxibXnndoF1cW:w NFqyXoEzOzN|NEOyOy=>
S462 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjpNVAxKM7:TR?= NFzX[W04OiCq NYrWcGF2TE2VTx?= MnHCRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NHnWR5gzOzN{OEGxOC=>
2884 NHzH[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDINVAxKM7:TR?= NF36TWo4OiCq Mo\wSG1UVw>? NVi1R3E6SXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M1jMSVI{OzJ6MUG0
2885 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfZOmVTOTByIN88US=> NWLVRnRYPzJiaB?= M2H4SmROW09? MkL4RZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? Mm\2NlM{OjhzMUS=
CRL-2396 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrZcWc5OTByIN88US=> MXv3ZZRmeg>? NVrnNZhOUUN3ME2wMlA6OiEQvF2= MXyyN|E2OzV{NB?=
TIB-48 NWfvVGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\UVVExOCEQvF2= NF;SNWd4[XSnch?= MV7JR|UxRTBwMEi4JO69VQ>? MViyN|E2OzV{NB?=
CRL-2396 MV3DfZRwfG:6aXOgRZN{[Xl? MWixJO69VQ>? NEjWVHg1QCCq MUT3ZZRmeg>? MUXJcoR2[2W|IHHwc5B1d3Orcx?= NXXFNmlvOjNzNUO1NlQ>
TIB-48 MoToR5l1d3SxeHnjJGF{e2G7 NX7Tb4ExOSEQvF2= M{HqU|Q5KGh? NH\kZmZ4[XSnch?= NEe5TWFKdmS3Y3XzJIFxd3C2b4Ppdy=> MojoNlMyPTN3MkS=
AGS MnPBR5l1d3SxeHnjJGF{e2G7 M4rBOlAvPSEQvF2= NUC5VYlmOjRiaB?= MVzEUXNQ MVnE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? Mm\VNlI6PzJ4MUG=
FLO-1 NF\YR2NEgXSxdH;4bYMhSXO|YYm= NX:zc4FEOC53IN88US=> MoLnNlQhcA>? NX3yT3hwTE2VTx?= MlLmSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? M{S0eFIzQTd{NkGx
OE33 NIjkdndEgXSxdH;4bYMhSXO|YYm= Mn\xNE42KM7:TR?= Mn;LNlQhcA>? MWfEUXNQ M1XBbWRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MViyNlk4OjZzMR?=
SKLMS MYHDfZRwfG:6aXOgRZN{[Xl? NHPieFQ4PSCwTR?= Mnz4PVYhcA>? NGnGeZdKdmS3Y3XzJIFxd3C2b4Ppdy=> NVnrSGVOOjJ6MkG5PVc>
Leio285 Mlm3R5l1d3SxeHnjJGF{e2G7 M2ntWFc2KG6P NU\CTWRGQTZiaB?= NFS0ZZdKdmS3Y3XzJIFxd3C2b4Ppdy=> MX[yNlgzOTl7Nx?=
Mes-Sa NVjWfW84S3m2b4TvfIlkKEG|c3H5 NGjZdGU4PSCwTR?= M2PsfFk3KGh? M2XlRWlv\HWlZYOgZZBweHSxc3nz M2LsWVIzQDJzOUm3
DAOY NUPRV2lES3m2b4TvfIlkKEG|c3H5 MYKxNEDPxE1? NHzyfHk4OiCq NEfBWJdFVVOR MV3JR|UxRTBwMESg{txO MlnmNlI3Pjl|M{W=
IMR32 MmDtR5l1d3SxeHnjJGF{e2G7 MWWxNEDPxE1? NULDS2JwPzJiaB?= MUTEUXNQ MWLJR|UxRTBwMEOg{txO NY\QeWo5OjJ4NkmzN|U>
Molt-4 NXzkXnI2S3m2b4TvfIlkKEG|c3H5 NXjz[mtROTBizszN MVO3NkBp NIHK[HdFVVOR NVvyemFnUUN3ME2wMlAzKM7:TR?= M{LYXFIzPjZ7M{O1
MOLM-13 NGjTemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr3XZB[OyEQvF2= NFXWNpQ4OiCq NUHic|BzTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> Ml7PNlI1QDh{NEm=
HL-60 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCweFJ5OyEQvF2= NXHHOHZrPzJiaB?= MVnEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M{XM[VIzPDh6MkS5
MV4-11 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGzJO69VQ>? MUC3NkBp MU\EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M1\PeVIzPDh6MkS5
SKM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\TbVMh|ryP MmTLO|IhcA>? MWrEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M{T5bVIzPDh6MkS5
SH2 NWOyfWRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C3O|Mh|ryP MWS3NkBp NHyzRnBFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MnLrNlI1QDh{NEm=
NOMO-1 NHjoSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqzJO69VQ>? M3LPfVczKGh? MkfSSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MU[yNlQ5QDJ2OR?=
OCL-AML2 NWq4Tld2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX21[2l{OyEQvF2= MYi3NkBp M{XkTWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NF;COpQzOjR6OEK0PS=>
PL-21 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxSXJqOyEQvF2= MlPBO|IhcA>? MVTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NE\LVnEzOjR6OEK0PS=>
KG-1 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrPUIVLOyEQvF2= M1ft[FczKGh? NGWz[3FFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NIrNWGkzOjR6OEK0PS=>
A172 MYHDfZRwfG:6aXOgRZN{[Xl? MYixNFAh|ryP MkexNlQhcA>? MYrEUXNQ MmDITWM2OD1yLkGyNEDPxE1? MVqyNlI4PDN7OR?=
U87 MlK3R5l1d3SxeHnjJGF{e2G7 M{S0TVExOCEQvF2= M{XSblI1KGh? MX7EUXNQ Mm[2TWM2OD1yLkGwOUDPxE1? NVLxR5RHOjJ{N{SzPVk>
U251 M3fWbWN6fG:2b4jpZ{BCe3OjeR?= NXGwUnFjOTByIN88US=> MVyyOEBp M2i4UmROW09? NHLJSnJKSzVyPUCuNVAxKM7:TR?= MX[yNlI4PDN7OR?=
T98 M4\mV2N6fG:2b4jpZ{BCe3OjeR?= NUPJcZZ1OTByIN88US=> MnPkNlQhcA>? MlrISG1UVw>? NETNUWJKSzVyPUCuNVI2KM7:TR?= NHT2dGgzOjJ5NEO5PS=>
LN18 NWjOWW9qS3m2b4TvfIlkKEG|c3H5 M2nvZ|ExOCEQvF2= MnXzNlQhcA>? M4LidmROW09? NH\scGJKSzVyPUCuNlExKM7:TR?= NVHO[4tSOjJ{N{SzPVk>
LN443 NYm0RlVMS3m2b4TvfIlkKEG|c3H5 M{K1elExOCEQvF2= NEC5SmgzPCCq MVTEUXNQ NFzpW2FKSzVyPUCuNlIxKM7:TR?= NYPzNWJMOjJ{N{SzPVk>
HF66 MXHDfZRwfG:6aXOgRZN{[Xl? NHHQSYkyODBizszN NYrncYlmOjRiaB?= NF7aXmNFVVOR MnXGTWM2OD1yLkKyOUDPxE1? NFG4eWUzOjJ5NEO5PS=>
HF2303 Ml;JR5l1d3SxeHnjJGF{e2G7 MUSxNFAh|ryP M1\WSlI1KGh? NWLkSFVUTE2VTx?= NVTtdYpUUUN3ME2wMlA3OCEQvF2= M{jtZVIzOjd2M{m5
HF2359 NX\YU5FyS3m2b4TvfIlkKEG|c3H5 M1fyelExOCEQvF2= NFzBU4szPCCq NEjxZppFVVOR NGeyPGFKSzVyPUCuNFYxKM7:TR?= NIjL[4gzOjJ5NEO5PS=>
HF2414 MnP3R5l1d3SxeHnjJGF{e2G7 M3PsPVExOCEQvF2= NU\hOWcyOjRiaB?= NGTOPWFFVVOR MVfJR|UxRTBwMEiwJO69VQ>? NGLRcmczOjJ5NEO5PS=>
A-673 NEm5SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zhO|ExKM7:TR?= NH3jNFc6PiCq NWTFXGZkTE2VTx?= MnjPTWM2OD1yLkCzNkDPxE1? MlntNlE1PDh3OUG=
TC-32 NVXEV4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fkcFExKM7:TR?= NFvrN2U6PiCq M1TLVWROW09? MnzCTWM2OD1yLkCzPUDPxE1? Mlq5NlE1PDh3OUG=
TC-71 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[xNEDPxE1? MkDpPVYhcA>? MkXXSG1UVw>? NHHyT3hKSzVyPUCuNVAzKM7:TR?= NXrjdIpjOjF2NEi1PVE>
SK-N-MC NHH5SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxNEDPxE1? NHfHcYM6PiCq M4X2NGROW09? NF7Rd2NKSzVyPUCuNFczKM7:TR?= NHzxZVczOTR2OEW5NS=>
CHLA-9 NGe3b3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXXdIkyOCEQvF2= Mlr6PVYhcA>? NIW5cpZFVVOR NUW5TYFvUUN3ME2wMlAyQCEQvF2= NYq1NXQ5OjF2NEi1PVE>
CHLA-10 NY\ZepRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXzc2hzOTBizszN MlzmPVYhcA>? Ml3YSG1UVw>? MVjJR|UxRTBwME[wJO69VQ>? M1XyW|IyPDR6NUmx
CHLA-25 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnMeGE5OTBizszN MkPXPVYhcA>? MV7EUXNQ NWi0PIZZUUN3ME2wMlE3QCEQvF2= Mni2NlE1PDh3OUG=
CHLA-32 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxNEDPxE1? M1v4SVk3KGh? NVTwcGVLTE2VTx?= MnL1TWM2OD1yLkGzOkDPxE1? MXqyNVQ1QDV7MR?=
CHLA-56 MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNEDPxE1? MVu5OkBp NVO1SoN6TE2VTx?= NWLRcYRVUUN3ME2xNEDPxE1? M3;xT|IyPDR6NUmx
CHLA-258 NGi5XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;RNVAh|ryP NYm2[mJPQTZiaB?= M3fHdmROW09? NW\QTmRRUUN3ME2wMlE{OiEQvF2= M2iwUVIyPDR6NUmx
COG-E-352 NYLxboE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNEDPxE1? MWe5OkBp NVXiWo91TE2VTx?= MlTFTWM2OD1yLkC0N{DPxE1? NX3UUYVuOjF2NEi1PVE>
CHLA-90 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\QVYVyOTBizszN MV[5OkBp NV2ybWs4TE2VTx?= NGXCZ4hKSzVyPUCuNFYyKM7:TR?= NH\wPWMzOTR2OEW5NS=>
CHLA-119 NV3Gboh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorSNVAh|ryP NHfyVZE6PiCq MX\EUXNQ NXvnW4N6UUN3ME2wMlAzOiEQvF2= M3;tNVIyPDR6NUmx
CHLA-122 NIPObXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz3NVAh|ryP NXjxbppXQTZiaB?= NXTyUoFtTE2VTx?= MVjJR|UxRTBwMEG5JO69VQ>? NGLJboEzOTR2OEW5NS=>
CHLA-136 M2PDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjDNVAh|ryP MUG5OkBp MUnEUXNQ M3rzfWlEPTB;MD6wN|kh|ryP MoXLNlE1PDh3OUG=
CHLA-140 NEezSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfKW2EyOCEQvF2= M13UbFk3KGh? M1LK[GROW09? MXTJR|UxRTBwMEK2JO69VQ>? MVWyNVQ1QDV7MR?=
LA-N-6 M{DGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNEDPxE1? M1Hjdlk3KGh? MVrEUXNQ NIjOPVlKSzVyPUCuNFU1KM7:TR?= MUKyNVQ1QDV7MR?=
NB-1643 M2jhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknqNVAh|ryP M1TZZ|k3KGh? MoPTSG1UVw>? NVTx[3V1UUN3ME2wMlA{PyEQvF2= MYGyNVQ1QDV7MR?=
NB-EBc1 NFO3cItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jyblExKM7:TR?= MlnrPVYhcA>? MUjEUXNQ NVfwT|BOUUN3ME2wMlA2OCEQvF2= M3jBOVIyPDR6NUmx
SK-N-BE-1 M2XVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\2VWx7OTBizszN MlfmPVYhcA>? NWjDVI5ITE2VTx?= M{LjR2lEPTB;MD6wNlgh|ryP M{PZVVIyPDR6NUmx
SK-N-BE-2 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXLNVAh|ryP MlrhPVYhcA>? MlTkSG1UVw>? MVHJR|UxRTBwMEO2JO69VQ>? M4XQb|IyPDR6NUmx
SMS-KAN MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? M1vt[Fk3KGh? NFiyS3VFVVOR MlvtTWM2OD1yLkCzOEDPxE1? MXSyNVQ1QDV7MR?=
SMS-KANR M2PHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xNEDPxE1? MU[5OkBp M1zPbGROW09? NYDsV45tUUN3ME2wMlAzPiEQvF2= M2T2O|IyPDR6NUmx
SMS-KCN M1v6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNEDPxE1? NUe4O2NSQTZiaB?= Mlf1SG1UVw>? MUDJR|UxRTBwMEG5JO69VQ>? Ml;tNlE1PDh3OUG=
SMS-KCNR NXPQOI5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XKO|ExKM7:TR?= MYi5OkBp M{XRO2ROW09? MUnJR|UxRTBwMEGwJO69VQ>? NFfER3IzOTR2OEW5NS=>
SMS-LHN Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\YVlExKM7:TR?= M1;iRlk3KGh? MYjEUXNQ M{nZPWlEPTB;MD6wN|Ih|ryP MUGyNVQ1QDV7MR?=
SMS-MSN NESxeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUO20yOCEQvF2= Ml7YPVYhcA>? NFvDTlJFVVOR MojwTWM2OD1yLkCyNkDPxE1? NUH4VYVnOjF2NEi1PVE>
SMS-SAN NG\qSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfq[GVKOTBizszN MlH6PVYhcA>? M4rhVmROW09? MofxTWM2OD1yLkCyNEDPxE1? NH\hOFIzOTR2OEW5NS=>
Granta-4 NXLlTm5mS3m2b4TvfIlkKEG|c3H5 NVrPd4s2OTBizszN MWS3JIQ> MnX1TWM2OD1yLkC0NEDPxE1? NULZZnA{OjF{OUG4Olc>
DB M2PWeWN6fG:2b4jpZ{BCe3OjeR?= NUHPO5NPOTBizszN NY[3[nRKPyCm NHzESWNKSzVyPUCuNFQzKM7:TR?= MmS5NlEzQTF6Nke=
RL M2LSVWN6fG:2b4jpZ{BCe3OjeR?= Mn7FNVAh|ryP NVzGOY55PyCm M{P2PWlEPTB;MD6wNVUh|ryP NGfzOY4zOTJ7MUi2Oy=>
K562 NW[5VXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNEDPxE1? MVy5OkBp Mli4TWM2OD1yLkC4O{DPxE1? NEXsPIkzOTB7MU[zNy=>
LAMA-84 NXy4[2gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq2NVAh|ryP M2r0eVk3KGh? MUjJR|UxRTBwMEW3JO69VQ>? MWGyNVA6OTZ|Mx?=
MM15 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K5eVQh|ryP NXjMTpNUPzJiaB?= NY\PS|NHTE2VTx?= NYexdHh4UUN3ME2wMlE{KM7:TR?= M3jlXVIxOzh{OES0
OPM1 NYrLRldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH0NHN4PCEQvF2= MVq3NkBp MWjEUXNQ NVX2RVFGUUN3ME2wMlA{KM7:TR?= MVWyNFM5Ojh2NB?=
RPM1 M{DRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX60JO69VQ>? Mkn6O|IhcA>? NVvNWXpHTE2VTx?= MmXLTWM2OD1zMD6zNkDPxE1? NI\o[GkzODN6Mki0OC=>
INA6 NXL2d4Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon6OEDPxE1? MnK4O|IhcA>? NHWzZ25FVVOR MYTJR|UxRTBwMECyJO69VQ>? MXSyNFM5Ojh2NB?=
OPM2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXHb3g{PCEQvF2= MUK3NkBp MkPjSG1UVw>? M4ruO2lEPTB;ND6zO{DPxE1? MV[yNFM5Ojh2NB?=
MM1R MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zpWVQh|ryP MknoO|IhcA>? MnGySG1UVw>? NX3Ue3RnUUN3ME2xMlY5KM7:TR?= NEHaNmkzODN6Mki0OC=>
DOX40 NV7GeVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rLbVQh|ryP MmnJO|IhcA>? Ml;6SG1UVw>? NX;jWZhDUUN3ME21MlQ5KM7:TR?= NFXTT2UzODN6Mki0OC=>
LR5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu1T5Y1KM7:TR?= MXm3NkBp MVzEUXNQ MUXJR|UxRTJwNUOg{txO M1\UbVIxOzh{OES0
U266 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfCRnY1KM7:TR?= NH\OT5I4OiCq NV31R3BZTE2VTx?= NX[4Z|FtUUN3ME2xMlQ{KM7:TR?= NVzNVG5nOjB|OEK4OFQ>
RD Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNEDPxE1? NF;RRVg6PiCq NG\teVhKSzVyPUCuNlI5KM7:TR?= NH7QVYMzODFyOEOzPC=>
Rh41 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;zS|ExKM7:TR?= NUTyTYlJQTZiaB?= NGPyXlZKSzVyPUCuNFkxKM7:TR?= M{X3c|IxOTB6M{O4
Rh30 M4P1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfCNVAh|ryP MlTGPVYhcA>? MlzwTWM2OD1yLkKzNEDPxE1? NF\0eVYzODFyOEOzPC=>
BT-12 M3ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGxNEDPxE1? NXrLNo5HQTZiaB?= MUjJR|UxRTBwME[wJO69VQ>? MX2yNFExQDN|OB?=
CHLA-266 M{nUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG5OHNzOTBizszN MnTqPVYhcA>? NVnOSVczUUN3ME2wMlA4OiEQvF2= NXH2RpY1OjBzMEizN|g>
TC-71 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LyZ|ExKM7:TR?= MVy5OkBp MWDJR|UxRTBwMUCyJO69VQ>? NGTPdXMzODFyOEOzPC=>
SJ-GBM2 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjSWWkyOCEQvF2= M4[xZlk3KGh? M2DVS2lEPTB;MD6wOVAh|ryP MWCyNFExQDN|OB?=
NALM-6 NEGzcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nDRVExKM7:TR?= MX:5OkBp NFLBXIdKSzVyPUCuNFYzKM7:TR?= NH7sVYQzODFyOEOzPC=>
COG-LL-317 NUO2dYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuxNEDPxE1? M1uwPVk3KGh? MXvJR|UxRTBwMES3JO69VQ>? MXuyNFExQDN|OB?=
RS4-11 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jESFExKM7:TR?= MWe5OkBp MoHtTWM2OD1yLkCxPEDPxE1? MmnjNlAyODh|M{i=
MOLT-4 M4Hhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvDNVAh|ryP MVG5OkBp MnvGTWM2OD1yLkCyOkDPxE1? NIrzVJozODFyOEOzPC=>
CCRF-CEM NVnaWXliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxNEDPxE1? NIfEdY06PiCq NHj2TJdKSzVyPUCuNFk1KM7:TR?= M4W3NVIxOTB6M{O4
Kasumi-1 M3;PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNEDPxE1? M3rmZlk3KGh? MV\JR|UxRTBwMUCzJO69VQ>? M{O4OlIxOTB6M{O4
Karpas-299 NFjIfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nkRlExKM7:TR?= MVu5OkBp MnywTWM2OD1yLkCzPEDPxE1? MXmyNFExQDN|OB?=
Ramos-RA1 NXfrbYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXexNEDPxE1? NF;zeWg6PiCq M4G1NmlEPTB;MD6xNlch|ryP NXzCO4UzOjBzMEizN|g>

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID